Alnylam Reports Huntingtin Protein Reduction in Drug Trial

The study shows significant protein decreases in patients but has yet to demonstrate slowed disease progression.

Updated on Oct. 24, 2026 in Alzheimer’s

Bold flat-color editorial illustration of a glass syringe on a tray, symbolizing medical research on Huntington's disease. — Alnylam Pharmaceuticals reported that its experimental drug brezosiran significantly lowered mutant huntingtin protein levels in a recent clinical trial. AI Illustration. Upload story photo >

Live Poll

Should medical trials prioritize reducing biological markers over showing direct improvements in patient disease symptoms?

Alnylam Pharmaceuticals announced that its experimental Huntington's disease drug, brezosiran, successfully reduced mutant huntingtin protein levels in a clinical trial. While the results demonstrate biological efficacy, the study did not yet prove that the treatment slows the progression of the disease.

Why it matters

Huntington's disease is a progressive, fatal condition, and reducing the mutant protein is a key therapeutic goal. This trial is critical for establishing the safety and tolerability of a new approach to managing the disorder.

Participants in the high-dose group achieved a mean reduction in spinal-fluid mutant huntingtin of 60% to 64% three months after a single dose. Results showed mean maximum reductions of 64.8% on SMCxPRO and 59.2% on NULISA assays.

The players

Alnylam Pharmaceuticals

This is a biopharmaceutical company that focuses on the discovery, development, and commercialization of RNA interference therapeutics.

University of British Columbia Hospital

This facility served as a research site for the clinical evaluation of the experimental drug.

The details

The randomized, double-blind study evaluated 48 adults aged 25 to 70 who received one intrathecal dose of brezosiran. Researchers observed no dose-related increases in inflammatory markers or neurofilament light chain over a 12-month follow-up period.

Sept. 10, 2026: Assessment date for serious adverse events among participants.
Oct. 23, 2026: Alnylam Pharmaceuticals announced the interim trial results.
2027: Alnylam plans to launch a placebo-controlled study to test efficacy.

Health Landscape

This trial follows the established pattern of testing huntingtin-lowering therapeutics by focusing first on biomarker reduction before long-term clinical outcomes. It represents a significant step in determining whether protein-level changes correlate with sustained patient improvements.

While the drug is not yet available, these results clarify the biological feasibility of using RNA interference to target the root cause of Huntington's disease. Patients and their families should monitor future trial phases to see if these protein reductions eventually lead to improved physical outcomes.

The takeaway

Although the observed protein reductions are a promising signal, the failure to demonstrate slowed disease progression highlights the complexity of treating neurodegenerative conditions. Researchers will continue to monitor whether these molecular changes translate into meaningful clinical benefits in upcoming studies.

What happens next

Alnylam Pharmaceuticals is scheduled to initiate a new placebo-controlled study in 2027 to evaluate whether the reduction of mutant huntingtin protein successfully slows the clinical progression of the disease.